CytomX Therapeutics, Inc.
|Company Name||CytomX Therapeutics, Inc.|
|Class Period||May 17, 2018 to May 13, 2020|
|Lead Plaintiff Motion Deadline||July 20, 2020|
On May 13, 2020, the Company made available abstracts for the Company’s clinical presentations for CX-072 and CX-2009. Results from the PROCLAIM-CX-072 clinical program revealed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and ipilimumab. Meanwhile, results from the PROCLAIM-CX-2009 clinical program showed “evidence” of clinical activity at doses at least 4 mg/kg 3x/week, but also suggested a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.
On this news, the Company’s share price fell $5.21 per share, or over 36%, to close at $9.23 per share on May 14, 2020, thereby injuring investors.
Submit Your Information
If you suffered a loss on your CytomX Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.